Biocon Limited's quarterly earnings report, debt reduction strategy, R&D investment, and CapEx plans for future growth ...

The surge in Biocon share price came after the company announced that United States Food and Drug Administration (USFDA) has ...

With the Bengaluru unit's clearance from the USFDA out of the window, investors are now eagerly waiting for regulatory ...

Shares of Biocon gained over 8 per cent after the US Food and Drug Administration (USFDA) classified its Bengaluru unit as ...

Biocon is a prominent global biopharmaceutical company driven by innovation, specialising in therapies for chronic conditions ...

Biocon Ltd shares jumped 8.4% on Monday after receiving a ‘Voluntary Action Indicated’ status from the USFDA for its ...

Bengaluru-based Biocon on Wednesday reported a consolidated net loss of Rs 16 crore for the second quarter ended September 30 ...

The Indian stock market closed in the red on Thursday, November 14, for the sixth consecutive session. The decline slowed ...

Biocon Academy announced a 100% placement success for Batch 6 of the Biocon Ramaiah Certificate Programme in Quality Control Analytical, achieved in a record 2.5 hours. The placement drive attracted ...

Biocon Ltd on Wednesday reported a consolidated net loss of Rs 16 crore for the second quarter ended September 30, 2024 on account of higher tax, based on geographical split of profits.

The brokerage maintains its Neutral stance on the stock, as the current valuation captures the earnings upside.

The 17th CPHI and PMEC India Expo in Greater Noida highlights pharma modernization and sustainability, hosting over 2,000 ...